07.21.25
For what pathophysiologic reasons is targeting the complement pathway a viable therapeutic route for treating geographic atrophy? And which pipeline therapeutic approaches could be useful to patients in the future? Anat Loewenstein, MD is joined by a world-class trio of retina specialists—Daniel Ting, MD, PhD; Paulo Eduardo Stanga, MD; and Patricio G. Schlottmann, MD—for a discussion exploring the state of play in GA from a global perspective. This podcast is part 1 of 2.
View full description +
Editorially independent content, supported by Astellas
Subscribe
09.04.25
ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDRDavid Lally, MD; and Ehsan Rahimy, MD
Editorially independent content, supported by Genentech
08.21.25
ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human GradersJohn Kitchens, MD; Krishna Mukkamala, MD
Editorially independent content, supported by Genentech
07.21.25
The State of Geographic Atrophy Around the Globe: Part 2 of 2Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD; Daniel Ting, MD, PhD
Editorially independent content, supported by Astellas
07.21.25
The State of Geographic Atrophy Around the Globe: Part 1 of 2Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD; Daniel Ting, MD, PhD
Editorially independent content, supported by Astellas
07.18.25
Diabetic Retinopathy Severity and Income StatusBen Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD
Editorially Independent Supported By Genentech and Neurotech.
07.07.25
GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing TherapyJudy Kim, MD; Sunir Garg, MD; Deepak Sambhara, MD; and Rishi Singh, MD
Editorially independent content, supported by Apellis
07.07.25
GA in 2025: Dosing Regimens, Drug Selection, and Ideal CandidatesJudy Kim, MD; Sunir Garg, MD; Deepak Sambhara, MD; and Rishi Singh, MD
Editorially independent content, supported by Apellis
Show More